Adherence to Treatment Recommendations for Chronic Obstructive Pulmonary Disease - Results from the Swedish National Airway Register

Introduction Swedish guidelines adhere to the international GOLD document regarding management of chronic obstructive pulmonary disease (COPD). Based on data from the Swedish National Airway Register (SNAR) the aim was to evaluate adherence to guidelines of pharmacological treatment of COPD in Swedish primary and secondary care. Methods During a period of 18 months, data on symptoms (CAT, mMRC), lung function, exacerbation history and pharmacological treatment from 15,595 COPD patients from 853 primary care and 125 secondary care clinics were collected from SNAR. Patients with a co-diagnosis of asthma were excluded. Patients were divided into four treatment groups: no pharmacological treatment, short-acting bronchodilators alone, long-acting bronchodilators alone and ICS alone or in combination with bronchodilators. Results Of the patients, 29% were in GOLD group A, 58% in group B, 2% in group C and 11% in group D. CAT score was ≥10 and mMRC score was below 2 in 30.9% of the patients and mMRC score was ≥2 and CAT score <10 in 4.2% of the patients. In 61.4% of the patients, no exacerbation was registered during the last year. Long-acting bronchodilators were prescribed for 78% and ICS for 46% of all patients. In groups A, B, C and D, respectively, 21%, 11%, 11% and 5% did not receive any inhaler therapy; 67%, 81%, 81% and 90% received long-acting bronchodilators; 33%, 46%, 55% and 71% received any ICS containing therapy and 19%, 34%, 39% and 61% received triple therapy. Discussion Data from the SNAR indicate that only a minority of COPD patients were untreated. There was a liberal use of ICS containing drug combinations in subjects who do not have an indication for ICS. A considerable proportion of subjects at high risk of exacerbations did not receive ICS treatment.

[1]  Adherence to GOLD Recommendations among Swiss Pulmonologists and General Practitioners , 2020, COPD.

[2]  M. Cazzola,et al.  A case scenario study on adherence to COPD GOLD recommendations by general practitioners in a rural area of southern Italy: The "progetto PADRE". , 2020, Respiratory medicine.

[3]  P. Dorinsky,et al.  Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. , 2020, The New England journal of medicine.

[4]  A. Lindberg,et al.  The Swedish National Airway Register (SNAR): development, design and utility to date , 2020, European clinical respiratory journal.

[5]  E. Kerwin,et al.  An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD , 2019, International journal of chronic obstructive pulmonary disease.

[6]  C. Janson,et al.  A Cross-Sectional Study Assessing Appropriateness Of Inhaled Corticosteroid Treatment In Primary And Secondary Care Patients With COPD In Sweden , 2019, International journal of chronic obstructive pulmonary disease.

[7]  E. Kerwin,et al.  Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial , 2019, Respiratory Research.

[8]  J. Vestbo,et al.  Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population , 2019, International journal of chronic obstructive pulmonary disease.

[9]  E. Wouters,et al.  Contribution of individual COPD assessment test (CAT) items to CAT total score and effects of pulmonary rehabilitation on CAT scores , 2018, Health and Quality of Life Outcomes.

[10]  P. Dorinsky,et al.  Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. , 2018, The Lancet. Respiratory medicine.

[11]  S. Rennard,et al.  Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. , 2018, The Lancet. Respiratory medicine.

[12]  M. Miravitlles,et al.  Should Patients Switched from D to B in the GOLD 2017 Classification be Discontinued from Inhaled Corticosteroids? , 2017, COPD.

[13]  A. Gayle,et al.  Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice , 2017, npj Primary Care Respiratory Medicine.

[14]  C. Janson,et al.  Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014 , 2017, European clinical respiratory journal.

[15]  J. Wedzicha,et al.  Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.

[16]  A. Kaplan Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice , 2015, International journal of chronic obstructive pulmonary disease.

[17]  D. Price,et al.  The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK , 2015, International journal of chronic obstructive pulmonary disease.

[18]  Dave Singh,et al.  Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. , 2015, Respiratory medicine.

[19]  E. Kerwin,et al.  Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. , 2014, The Lancet. Respiratory medicine.

[20]  C. Stonham,et al.  COPD Exacerbation Frequency, Pharmacotherapy and Resource Use: An Observational Study in UK Primary Care , 2013, COPD.

[21]  F. Martinez,et al.  Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. , 2013, The Lancet. Respiratory medicine.

[22]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[23]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[24]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[25]  tefan,et al.  LONG-TERM TREATMENT WITH INHALED BUDESONIDE IN PERSONS WITH MILD CHRONIC OBSTRUCTIVE PULMONARY DISEASE WHO CONTINUE SMOKING , 2000 .

[26]  D. Postma,et al.  Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking , 1999 .

[27]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[28]  D. Postma,et al.  Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. , 1999, The New England journal of medicine.